
|Articles|November 1, 2003
New drug targets considered for erectile dysfunction
Author(s)Robert H. Carlson
Paris-Basic research in erectile dysfunction therapy is being hamperedby the attitude of some funding bodies that phosphodiesterase type-5 inhibitorsalone have solved all problems, according to a special committee convenedat the 2nd International Consultation on Erectile and Sexual Dysfunctionshere.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
ORIC-944 shows promise in combination with ARPIs for mCRPC
2
Radioligands and ADT alternatives emerge in prostate cancer treatment
3
Jason Hafron, MD, recaps prostate cancer data from ESMO 2025
4
Beyond PSA: Jonathan Henderson, MD, on precision tools for prostate cancer
5



















